Mike Matson
Stock Analyst at Needham
(3.42)
# 995
Out of 5,118 analysts
536
Total ratings
46.88%
Success rate
4.49%
Average return
Main Sectors:
Stocks Rated by Mike Matson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Buy | $326 → $388 | $316.97 | +22.41% | 13 | Dec 17, 2025 | |
| HAE Haemonetics | Downgrades: Hold | n/a | $80.28 | - | 16 | Dec 15, 2025 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $70 → $84 | $76.45 | +9.88% | 5 | Dec 10, 2025 | |
| TMDX TransMedics Group | Maintains: Buy | $148 → $166 | $124.20 | +33.66% | 14 | Dec 8, 2025 | |
| SYK Stryker | Reiterates: Buy | $448 | $354.22 | +26.48% | 10 | Nov 14, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Buy | $3 | $1.09 | +175.23% | 22 | Nov 13, 2025 | |
| IMDX Insight Molecular Diagnostics | Maintains: Buy | $4.25 → $9 | $6.37 | +41.29% | 2 | Nov 11, 2025 | |
| AORT Artivion | Maintains: Buy | $50 → $58 | $46.31 | +25.24% | 20 | Nov 7, 2025 | |
| PSNL Personalis | Maintains: Buy | $7 → $10 | $8.14 | +22.85% | 21 | Nov 5, 2025 | |
| VCYT Veracyte | Maintains: Buy | $41 → $44 | $42.49 | +3.55% | 18 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $108 | $87.39 | +23.58% | 31 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $26 | $17.34 | +49.94% | 24 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $74.50 | - | 22 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $121 | $96.06 | +25.96% | 34 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $14.62 | - | 21 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $64 | $62.87 | +1.80% | 27 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $12.28 | +14.01% | 27 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $96.52 | - | 21 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $49 | $27.39 | +78.90% | 16 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $45 | $40.33 | +11.58% | 35 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $61 | $40.80 | +49.51% | 25 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 | $6.80 | +76.47% | 19 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $132.76 | - | 25 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $147.87 | - | 5 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $255.42 | - | 11 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $122.76 | - | 9 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $90.77 | - | 26 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $244.76 | - | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $20.36 | +106.29% | 2 | May 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $75 | $88.41 | -15.17% | 1 | Feb 18, 2021 |
Penumbra
Dec 17, 2025
Maintains: Buy
Price Target: $326 → $388
Current: $316.97
Upside: +22.41%
Haemonetics
Dec 15, 2025
Downgrades: Hold
Price Target: n/a
Current: $80.28
Upside: -
Establishment Labs Holdings
Dec 10, 2025
Maintains: Buy
Price Target: $70 → $84
Current: $76.45
Upside: +9.88%
TransMedics Group
Dec 8, 2025
Maintains: Buy
Price Target: $148 → $166
Current: $124.20
Upside: +33.66%
Stryker
Nov 14, 2025
Reiterates: Buy
Price Target: $448
Current: $354.22
Upside: +26.48%
Lucid Diagnostics
Nov 13, 2025
Reiterates: Buy
Price Target: $3
Current: $1.09
Upside: +175.23%
Insight Molecular Diagnostics
Nov 11, 2025
Maintains: Buy
Price Target: $4.25 → $9
Current: $6.37
Upside: +41.29%
Artivion
Nov 7, 2025
Maintains: Buy
Price Target: $50 → $58
Current: $46.31
Upside: +25.24%
Personalis
Nov 5, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $8.14
Upside: +22.85%
Veracyte
Nov 5, 2025
Maintains: Buy
Price Target: $41 → $44
Current: $42.49
Upside: +3.55%
Oct 31, 2025
Reiterates: Buy
Price Target: $108
Current: $87.39
Upside: +23.58%
Oct 29, 2025
Maintains: Buy
Price Target: $42 → $26
Current: $17.34
Upside: +49.94%
Oct 21, 2025
Reiterates: Hold
Price Target: n/a
Current: $74.50
Upside: -
Oct 17, 2025
Reiterates: Buy
Price Target: $121
Current: $96.06
Upside: +25.96%
Oct 10, 2025
Reiterates: Hold
Price Target: n/a
Current: $14.62
Upside: -
Sep 3, 2025
Reiterates: Buy
Price Target: $64
Current: $62.87
Upside: +1.80%
Aug 29, 2025
Maintains: Buy
Price Target: $8 → $14
Current: $12.28
Upside: +14.01%
Aug 14, 2025
Reiterates: Hold
Price Target: n/a
Current: $96.52
Upside: -
Aug 7, 2025
Maintains: Buy
Price Target: $57 → $49
Current: $27.39
Upside: +78.90%
Jul 30, 2025
Maintains: Buy
Price Target: $44 → $45
Current: $40.33
Upside: +11.58%
Jun 12, 2025
Downgrades: Hold
Price Target: $61
Current: $40.80
Upside: +49.51%
May 22, 2025
Upgrades: Buy
Price Target: $12
Current: $6.80
Upside: +76.47%
Apr 10, 2025
Reiterates: Hold
Price Target: n/a
Current: $132.76
Upside: -
Apr 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $147.87
Upside: -
Apr 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $255.42
Upside: -
Mar 12, 2025
Reiterates: Hold
Price Target: n/a
Current: $122.76
Upside: -
Feb 7, 2025
Reiterates: Hold
Price Target: n/a
Current: $90.77
Upside: -
Jan 31, 2025
Reiterates: Hold
Price Target: n/a
Current: $244.76
Upside: -
May 4, 2021
Maintains: Buy
Price Target: $34 → $42
Current: $20.36
Upside: +106.29%
Feb 18, 2021
Maintains: Buy
Price Target: $65 → $75
Current: $88.41
Upside: -15.17%